NFE2L2 and non-small cell lung carcinoma: The dual inhibition of glycolysis and glutaminolysis by the mTOR inhibitor sapanisertib (also named MLN0128, INK128 or TAK-228) and the glutaminase inhibitor telaglenastat (CB-839) to target NRF2-addicted NSCLC is currently in a clinical trial [141,142].